Iatrogenic and idiopathic acute myelogenous leukemia: A comparison of clinical features and treatment complications

C. K.Oladipupo Williams, Janet Cuttner, Takao Ohnuma, Edward P. Ambinder, Paulo P.C. Ferreira, James F. Holland

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We have compared the clinical and laboratory features as well as treatment complications observed in 6 patients with iatrogenic acute myelogenous leukemia (I-AML) with those of 26 patients with idiopathic acute myelogenous leukemia (AML). I-AML patients were significantly younger and their disease appeared less virulent on admission than in the AML patients. Following identical chemotherapy, hemorrhagic complications and the need for platelet support were found to be similar for both groups. Major infections, including systemic candidiases and Gram-negative septicemias, occurred 3 times more frequently among I-AML than AML patients. More marked suppression and delayed regeneration of the bone marrow also occurred in I-AML patients. These observations and other factors, such as post-splenectomy state and inherent immune deficiency among surgically staged lymphoma patients as well as radiation induced immunologic impairment, may have contributed to the increased propensity to develop infection observed in this group of patients. Five of the 6 I-AML and 17 of the 26 AML patients achieved remission. We attribute the satisfactory outcome in our I-AML patients to treatment in a protective environment and availability of facilities for hematologic supportive care.

Original languageEnglish
Pages (from-to)59-66
Number of pages8
JournalMedical Oncology and Tumor Pharmacotherapy
Volume4
Issue number2
DOIs
StatePublished - Jun 1987

Keywords

  • Hematological supportive care
  • Iatrogenic acute leukemia
  • Infection complications
  • Infection in post-splenectomy state
  • Leukemia chemotherapy

Fingerprint

Dive into the research topics of 'Iatrogenic and idiopathic acute myelogenous leukemia: A comparison of clinical features and treatment complications'. Together they form a unique fingerprint.

Cite this